Skip to content
TerminatedNot applicableResults posted

Role Of Non-Specific Effects in The Treatment of Depression With Esketamine

NCT05910775 · ROSETTE · Yale University

Closed to entry
Status
Not accepting participants
Not applicable
Phase
1
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

The investigators aim to examine the magnitude of non-specific effects in the treatment of depressive episodes with esketamine, by providing patients in the intervention group with a pretreatment presentation and post-treatment follow up session, to assess whether nonspecific effects can be used effectively to improve the effectiveness of treatment with esketamine.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Group Difference in Change in Question 6 Score on Treatment Credibility and Expectancy Scale (CEQ-6)

    Measured over baseline and after presentation (before treatment 1), up to 30 days

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Participants must be either male or female and at least 18 years old * Deemed clinically appropriate to receive esketamine by a Yale Interventional Psychiatry physician. * Written consent for the study procedures * Ability and willingness, in the investigator's judgement, to comply with the study schedule, treatment plan, and other trial requirements for the duration of the study. Exclusion Criteria: * Hearing or visual impairment to the degree that would interfere with ability to view the presentation * Difficulty in understanding spoken or written English * Unable to provide informed consent * Dementia or other cognitive disorder or intellectual disability that would impair the subject's ability to understand the presentation (per investigator judgment) * Any other medical or psychiatric comorbidity that the investigator judges would put the participant at additional undue risk due to study participation or would impair subject's ability to participate in the study. * Previous Esketamine or ketamine treatment * Unable to give informed consent * Was previously enrolled/randomized into the trial

Where

1 study site

FacilityCityRegionCountry
Yale Psychiatry Hospital Interventional Psychiatry Services (IPS) unitNew HavenConnecticutUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT05910775 on ClinicalTrials.gov →

Last updated in the registry 2026-01-14. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits